Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sentrip (tadalafil)
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sentrip is an oral dissolving film (ODF) formulation of tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor. Developed by C.L. Pharm using their proprietary film technology, it is indicated for the treatment of erectile dysfunction. By inhibiting PDE5, tadalafil prevents the degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum, leading to smooth muscle relaxation and increased blood flow to the penis during sexual stimulation. The ODF formulation allows for rapid dissolution in the mouth without the need for water, offering a convenient and discreet administration method compared to traditional tablets.
- Brand names
- Sentrip
- Other names
- Tadalafil ODFTadalafil Oral Dissolving Film
02
Targets
PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on Sentrip (tadalafil).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sentrip (tadalafil).